New treatment agents for advanced small cell and non-small cell lung cancer

P. A. Bunn, Karen Kelly

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The cure rate for lung cancer remains low (13%) primarily due to early systemic spread and the inability to cure systemic disease. These facts have led to pessimism regarding the role of chemotherapy, especially in non-small cell lung cancers. However, recent randomized trials demonstrated that chemotherapy significantly prolongs survival in advanced (stages IIIB and IV) and locally advanced (stages IIIA and IIIB) non-small cell lung cancers. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is an active agent in both non-small and small cell lung cancers, producing objective response rates as high as any other active agent. Early combination studies show even higher response rates when paclitaxel is combined with cisplatin or carboplatin. Ultimately, randomized trials will be needed to define the optimal use of paclitaxel and other recently developed new agents in lung cancer.

Original languageEnglish (US)
Pages (from-to)53-63
Number of pages11
JournalSeminars in Oncology
Volume22
Issue number3 SUPPL. 6
StatePublished - 1995
Externally publishedYes

Fingerprint

Paclitaxel
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Drug Therapy
Carboplatin
Small Cell Lung Carcinoma
Therapeutics
Cisplatin

ASJC Scopus subject areas

  • Oncology

Cite this

New treatment agents for advanced small cell and non-small cell lung cancer. / Bunn, P. A.; Kelly, Karen.

In: Seminars in Oncology, Vol. 22, No. 3 SUPPL. 6, 1995, p. 53-63.

Research output: Contribution to journalArticle

@article{6904faf839ff4ed0a35558090d0d315b,
title = "New treatment agents for advanced small cell and non-small cell lung cancer",
abstract = "The cure rate for lung cancer remains low (13{\%}) primarily due to early systemic spread and the inability to cure systemic disease. These facts have led to pessimism regarding the role of chemotherapy, especially in non-small cell lung cancers. However, recent randomized trials demonstrated that chemotherapy significantly prolongs survival in advanced (stages IIIB and IV) and locally advanced (stages IIIA and IIIB) non-small cell lung cancers. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is an active agent in both non-small and small cell lung cancers, producing objective response rates as high as any other active agent. Early combination studies show even higher response rates when paclitaxel is combined with cisplatin or carboplatin. Ultimately, randomized trials will be needed to define the optimal use of paclitaxel and other recently developed new agents in lung cancer.",
author = "Bunn, {P. A.} and Karen Kelly",
year = "1995",
language = "English (US)",
volume = "22",
pages = "53--63",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 6",

}

TY - JOUR

T1 - New treatment agents for advanced small cell and non-small cell lung cancer

AU - Bunn, P. A.

AU - Kelly, Karen

PY - 1995

Y1 - 1995

N2 - The cure rate for lung cancer remains low (13%) primarily due to early systemic spread and the inability to cure systemic disease. These facts have led to pessimism regarding the role of chemotherapy, especially in non-small cell lung cancers. However, recent randomized trials demonstrated that chemotherapy significantly prolongs survival in advanced (stages IIIB and IV) and locally advanced (stages IIIA and IIIB) non-small cell lung cancers. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is an active agent in both non-small and small cell lung cancers, producing objective response rates as high as any other active agent. Early combination studies show even higher response rates when paclitaxel is combined with cisplatin or carboplatin. Ultimately, randomized trials will be needed to define the optimal use of paclitaxel and other recently developed new agents in lung cancer.

AB - The cure rate for lung cancer remains low (13%) primarily due to early systemic spread and the inability to cure systemic disease. These facts have led to pessimism regarding the role of chemotherapy, especially in non-small cell lung cancers. However, recent randomized trials demonstrated that chemotherapy significantly prolongs survival in advanced (stages IIIB and IV) and locally advanced (stages IIIA and IIIB) non-small cell lung cancers. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is an active agent in both non-small and small cell lung cancers, producing objective response rates as high as any other active agent. Early combination studies show even higher response rates when paclitaxel is combined with cisplatin or carboplatin. Ultimately, randomized trials will be needed to define the optimal use of paclitaxel and other recently developed new agents in lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0029019686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029019686&partnerID=8YFLogxK

M3 - Article

C2 - 7597434

AN - SCOPUS:0029019686

VL - 22

SP - 53

EP - 63

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 6

ER -